<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02254707</url>
  </required_header>
  <id_info>
    <org_study_id>1201.14</org_study_id>
    <nct_id>NCT02254707</nct_id>
  </id_info>
  <brief_title>Evaluation of the Antiviral Pharmacodynamic Effect, Safety, and Pharmacokinetics of Escalating Doses of BILB 1941 ZW to Patients With Chronic Hepatitis C Genotype 1 Virus Infection</brief_title>
  <official_title>A Multinational Randomised, Double-blind, Placebo Controlled Study to Evaluate the Antiviral Pharmacodynamic Effect, Safety, and Pharmacokinetics of Escalating Doses of BILB 1941 ZW Oral Solution Administered Q8H for Five Days to Patients With Chronic Hepatitis C Genotype 1 Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To assess the antiviral effect, safety and pharmacokinetics of rising doses of 10 mg, 20 mg,
      40 mg, 60 mg, 80 mg, 100 mg, 150 mg, 200 mg, 300 mg, 450 mg, 650 mg, 900 mg oral BILB 1941 ZW
      administered Q8H in a polyethyleneglycol 400 (PEG 400): distilled water: Tromethamine (TRIS)
      drinking solution for five days to patients with chronic HCV genotype 1 infection
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in virus load (VL)</measure>
    <time_frame>Up to day 6</time_frame>
    <description>determined by IU per ml serum from baseline by &gt; 1.0 log10 step</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>Up to 14 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax (time from dosing to maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>Up to 14 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCτ,1 (area under the concentration-time curve of the analyte in plasma over a uniform dosing interval τ after administration of the first dose)</measure>
    <time_frame>Up to 14 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>Up to 14 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>%AUCtz-∞ (the percentage of the AUC0-∞ that is obtained by extrapolation)</measure>
    <time_frame>Up to 14 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz (terminal rate constant in plasma)</measure>
    <time_frame>Up to 14 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 (terminal half-life of the analyte in plasma)</measure>
    <time_frame>Up to 14 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F (apparent clearance of the analyte in plasma after extravascular administration)</measure>
    <time_frame>Up to 14 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular administration)</measure>
    <time_frame>Up to 14 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant changes in vital signs</measure>
    <time_frame>Up to 14 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant changes in body temperature</measure>
    <time_frame>Up to 14 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal findings in electrocardiogram (ECG)</measure>
    <time_frame>Up to 14 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal changes in clinical laboratory parameters</measure>
    <time_frame>Up to 14 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Up to 14 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal findings in physical examination</measure>
    <time_frame>Up to 14 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator assessed tolerability on a 4 point scale</measure>
    <time_frame>Up to 14 days after first drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>BILB 1941 ZW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating Doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BILB 1941 ZW</intervention_name>
    <arm_group_label>BILB 1941 ZW</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult males from 18 - 65 years

          2. Written informed consent consistent with ICH (International Conference on
             Harmonisation)/GCP (Good Clinical Practice) and local legislation given prior to any
             study procedures

          3. Chronic HCV infection demonstrated by positive HCV IgG Antibody

          4. HCV genotype 1 which has to be confirmed by central laboratory test before Visit 2

          5. Liver biopsy consistent with active Hepatitis C virus (HCV) infection obtained within
             the last 24 months showing minimal to mild liver fibrosis and without cirrhosis (Ishak
             or Metavir grade &lt;= 2)

          6. HCV ribonucleic acid (RNA) load greater than 100,000 IU RNA per ml serum at screening

          7. Willing to abstain from alcohol during the screening, treatment and until completion
             of the study (visit 11)

        Exclusion Criteria:

          1. Males not using an adequate form of contraception (condom, sterilisation at least 6
             months post operation) in case their partner is of childbearing potential and is not
             using an adequate form of contraception (hormonal contraceptives, oral or
             injectable/implantable, intra-uterine device (IUD).

          2. Any other or additional plausible cause for chronic liver disease, including the
             presence of other viruses known or suspected to cause hepatitis

          3. Evidence of decompensated liver disease: ascites, portal hypertension or hepatic
             encephalopathy

          4. Positive test for human immunodeficiency virus (HIV) or Hepatitis B surface (HBs)
             antigen at screening

          5. Current alcohol or drug abuse, or history of the same, within the past twelve (12)
             months. All patients must abstain from alcohol from enrolment until completion of the
             study (visit 11).

          6. Any concurrent medical illness or disease requiring treatment or concomitant
             medications

          7. History of malignancy (except for previously cured squamous cell or basal cell
             carcinoma)

          8. Usage of any investigational drug within thirty (30) days prior to enrolment or 5
             halflives, whichever is longer; or the planned usage of an investigational drug during
             the course of the current study

          9. Patients treated with interferon and/or ribavirin within 6 months prior to screening

         10. Planned or concurrent usage of any other pharmacological therapy at screening, or
             during the trial period, including any antiviral therapy or vaccination

         11. Known hypersensitivity to drugs or excipients

         12. Patients with any one of the following laboratory values at screening:

               -  Alanine transaminase (ALT) or Aspartate transaminase (AST) &gt; 2.5 x upper limit of
                  normal (ULN) (at screening and during the last 3 months before screening
                  demonstrated by at least 2 further determinations)

               -  Total bilirubin &gt; 1x ULN

               -  Alkaline phosphatase &gt; 1.5x ULN

               -  Prothrombin time (INR, prolonged) &gt; 1.5

               -  Platelet count &lt; 100,000 / mm3

               -  Hemoglobin &lt; 10.5 g/dL

               -  White blood cell count &lt; 2,000 / mm3

         13. Patients with any clinically significant laboratory abnormalities based on the
             investigator's medical assessment at screening

         14. Positive urine test for drug abuse at screening

         15. Patients with known Gilbert's disease

         16. Prior randomisation to active treatment with BILB 1941 ZW into dose groups 3 - 9 of
             this trial, or previous re-treatment based on amendment 2. To support selection,
             centers will receive lists of the placebo patients of the previous dose levels,
             however, only for each center separately

         17. Inability to comply with the protocol
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2014</study_first_submitted>
  <study_first_submitted_qc>October 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2014</study_first_posted>
  <last_update_submitted>October 1, 2014</last_update_submitted>
  <last_update_submitted_qc>October 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiviral Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

